Literature DB >> 9007695

Endocrine mechanisms of suppressive effect of low dose estrogen-antiandrogen treatment on androgen-dependent organs of male rats.

A G Reznikov1, S V Varga, L V Chaikovskaya, L V Tarasenko, L I Polyakova.   

Abstract

The effects of low doses of hexestrol (Hex) (2-40 micrograms/kg bw) and flutamide (FI) (10 mg/kg bw) on some endocrine mechanisms in mature intact male rats are described in the present paper. It has been shown that each preparation, administered separately for 10 days, induced a moderate decrease in the weight of the ventral prostate (VP), anterior prostate lobe or coagulating gland (CG) and seminal vesicles (SV), in the DNA content and number of cells in the VP. 5 alpha-reductase activity was also decreased; the epithelium secretory activity of the VP was suppressed. After combined FI (10 mg/kg bw) and Hex (40 micrograms/kg bw) the following castration-like effects were observed: an abrupt fall in the weight of the accessory sexual glands, a decrease of DNA level and cell number in the VP as well as a suppression of the production of 5 alpha-reductase metabolites in this structure. Histologically, a marked degenerative changes in the VP secretory epithelium was observed; on the contrary an hyperplasia of connective and smooth muscle cells was evident. When FI alone was administered to rat, the above-mentioned changes were accompanied by a pronounced elevation of plasma bio-LH and testosterone (T) levels, also an increase of testicular delta 5-3 beta-hydroxysteroid dehydrogenase activity was observed. On the contrary, when Hex was administered alone or in combination with FI, bio-LH and T levels and enzyme activity decreased. We conclude that Hex administration in low doses, in combination with FI, could be an alternative method for a complete androgen blockade of the accessory sexual glands.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9007695     DOI: 10.1007/BF03349034

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  15 in total

1.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

2.  Direct inhibitory effect of estrogen on Leydig cell function of hypophysectomized rats.

Authors:  A J Hsueh; M L Dufau; K J Catt
Journal:  Endocrinology       Date:  1978-10       Impact factor: 4.736

3.  Estrogen and castration-induced effects on canine prostatic fine structure and C-19-steroid metabolism.

Authors:  I Leav; R F Morfin; P Ofner; L F Cavazos; E B Leeds
Journal:  Endocrinology       Date:  1971-08       Impact factor: 4.736

4.  Problems associated with the in vitro bioassay of serum luteinizing hormone (LH) on mouse Leydig cell preparations: methodological aspects.

Authors:  G F Baraghini; M F Celani; A A Zaidi; D Cavani; E Baraldi; S Seghedoni; M Bazzani; V Montanini
Journal:  J Endocrinol Invest       Date:  1984       Impact factor: 4.256

5.  Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.

Authors:  E D Crawford; J A Allen
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

6.  Effects of a non-steroidal antiandrogen on sexual behavior and pituitary-gonadal function in the male rat.

Authors:  P Södersten; G Gray; D A Damassa; E R Smith; J M Davidson
Journal:  Endocrinology       Date:  1975-12       Impact factor: 4.736

7.  The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins.

Authors:  L Hellman; H L Bradlow; S Freed; J Levin; R S Rosenfeld; W F Whitmore; B Zumoff
Journal:  J Clin Endocrinol Metab       Date:  1977-12       Impact factor: 5.958

8.  Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement.

Authors:  H F English; R J Santen; J T Isaacs
Journal:  Prostate       Date:  1987       Impact factor: 4.104

9.  Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience.

Authors:  F Labrie; A Dupont; L Cusan; J Gomez; J Emond; G Monfette
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

10.  Efficacy and advantages in the use of low doses of Anandron and estrogen combination in the treatment of prostate cancer.

Authors:  B R Rao; A A Geldof; C L van der Wilt; H J de Voogt
Journal:  Prostate       Date:  1988       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.